Keyphrases
Hairy Cell Leukemia
100%
2-chlorodeoxyadenosine
100%
Malignant B Cells
33%
Clinical Relapse
33%
Long-term Survival
33%
Relapsed Disease
33%
New Agents
33%
Rituximab
33%
Complete Remission
33%
Refractory Disease
33%
Repeated Administration
33%
Minimal Residual Disease
33%
Remission Rate
33%
B-cell Clone
33%
Purine Analogues
33%
Chronic Lymphoproliferative Disorders
33%
Second Complete Remission
33%
Long-term Disease-free Survival
33%
Cytoplasmic Projections
33%
BL22
33%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Cladribine
100%
Hairy Cell Leukemia
100%
Lymphoproliferative Disease
33%
Rituximab
33%
Disease Free Survival
33%
Long Term Survival
33%
Purine Derivative
33%
Purine
33%
Minimal Residual Disease
33%
Diseases
33%
Medicine and Dentistry
Cladribine
100%
Hairy Cell Leukemia
100%
Disease Free Survival
33%
Minimal Residual Disease
33%
Spontaneous Remission
33%
Rituximab
33%
Long Term Survival
33%
B Cell
33%
Purine
33%
Chronic Lymphoproliferative Disorder
33%
Diseases
33%